Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity

Leslie Muldoon, Michael A. Pagel, Joao Prola Netto, Edward Neuwelt

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We tested the hypothesis that intra-arterial (IA) infusion of temozolomide into the internal carotid artery would safely improve drug delivery to brain and enhance chemotherapy efficacy in a chemosensitive rat brain tumor model. Quantitative autoradiography after 25 µCi 14C-temozolomide was given by oral, intravenous, or IA route of administration, or IA with osmotic blood–brain barrier disruption (BBBD) (n = 5–7 per group) showed that both IA and IA/BBBD administration increased drug delivery in tumor by over threefold compared to normal brain (P 2) increased median survival when given by oral (25.5 days), intravenous (25.5 days), or IA (33 days) route of administration, compared to 17.5 days in untreated controls (n = 8 per group; overall P 2 IA. Upon initiation of the second course of IA infusion the patient had increased heart rate, blood pressure, and rash, and the procedure was terminated without sequelae. Follow up IA infusion of temozolomide diluent in normal rats showed damaged cerebrovasculature as determined by dye leakage. These results demonstrate that IA infusion of temozolomide was toxic, with or without BBBD. We conclude that under the current formulation temozolomide is not safe for IA infusion in patients.

Original languageEnglish (US)
Pages (from-to)447-454
Number of pages8
JournalJournal of Neuro-Oncology
Volume126
Issue number3
DOIs
StatePublished - Feb 1 2016

Fingerprint

temozolomide
Intra Arterial Infusions
Neoplasm Metastasis
Brain
Poisons
Internal Carotid Artery
Exanthema
Autoradiography
Brain Neoplasms
Pharmaceutical Preparations
Coloring Agents
Heart Rate
Blood Pressure
Drug Therapy
Survival

Keywords

  • Animal model
  • Case study
  • Chemotherapy
  • Intra-arterial infusion

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. / Muldoon, Leslie; Pagel, Michael A.; Netto, Joao Prola; Neuwelt, Edward.

In: Journal of Neuro-Oncology, Vol. 126, No. 3, 01.02.2016, p. 447-454.

Research output: Contribution to journalArticle

@article{06ce432a21934731b44adb9396dd9af9,
title = "Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity",
abstract = "We tested the hypothesis that intra-arterial (IA) infusion of temozolomide into the internal carotid artery would safely improve drug delivery to brain and enhance chemotherapy efficacy in a chemosensitive rat brain tumor model. Quantitative autoradiography after 25 µCi 14C-temozolomide was given by oral, intravenous, or IA route of administration, or IA with osmotic blood–brain barrier disruption (BBBD) (n = 5–7 per group) showed that both IA and IA/BBBD administration increased drug delivery in tumor by over threefold compared to normal brain (P 2) increased median survival when given by oral (25.5 days), intravenous (25.5 days), or IA (33 days) route of administration, compared to 17.5 days in untreated controls (n = 8 per group; overall P 2 IA. Upon initiation of the second course of IA infusion the patient had increased heart rate, blood pressure, and rash, and the procedure was terminated without sequelae. Follow up IA infusion of temozolomide diluent in normal rats showed damaged cerebrovasculature as determined by dye leakage. These results demonstrate that IA infusion of temozolomide was toxic, with or without BBBD. We conclude that under the current formulation temozolomide is not safe for IA infusion in patients.",
keywords = "Animal model, Case study, Chemotherapy, Intra-arterial infusion",
author = "Leslie Muldoon and Pagel, {Michael A.} and Netto, {Joao Prola} and Edward Neuwelt",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s11060-015-2000-1",
language = "English (US)",
volume = "126",
pages = "447--454",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity

AU - Muldoon, Leslie

AU - Pagel, Michael A.

AU - Netto, Joao Prola

AU - Neuwelt, Edward

PY - 2016/2/1

Y1 - 2016/2/1

N2 - We tested the hypothesis that intra-arterial (IA) infusion of temozolomide into the internal carotid artery would safely improve drug delivery to brain and enhance chemotherapy efficacy in a chemosensitive rat brain tumor model. Quantitative autoradiography after 25 µCi 14C-temozolomide was given by oral, intravenous, or IA route of administration, or IA with osmotic blood–brain barrier disruption (BBBD) (n = 5–7 per group) showed that both IA and IA/BBBD administration increased drug delivery in tumor by over threefold compared to normal brain (P 2) increased median survival when given by oral (25.5 days), intravenous (25.5 days), or IA (33 days) route of administration, compared to 17.5 days in untreated controls (n = 8 per group; overall P 2 IA. Upon initiation of the second course of IA infusion the patient had increased heart rate, blood pressure, and rash, and the procedure was terminated without sequelae. Follow up IA infusion of temozolomide diluent in normal rats showed damaged cerebrovasculature as determined by dye leakage. These results demonstrate that IA infusion of temozolomide was toxic, with or without BBBD. We conclude that under the current formulation temozolomide is not safe for IA infusion in patients.

AB - We tested the hypothesis that intra-arterial (IA) infusion of temozolomide into the internal carotid artery would safely improve drug delivery to brain and enhance chemotherapy efficacy in a chemosensitive rat brain tumor model. Quantitative autoradiography after 25 µCi 14C-temozolomide was given by oral, intravenous, or IA route of administration, or IA with osmotic blood–brain barrier disruption (BBBD) (n = 5–7 per group) showed that both IA and IA/BBBD administration increased drug delivery in tumor by over threefold compared to normal brain (P 2) increased median survival when given by oral (25.5 days), intravenous (25.5 days), or IA (33 days) route of administration, compared to 17.5 days in untreated controls (n = 8 per group; overall P 2 IA. Upon initiation of the second course of IA infusion the patient had increased heart rate, blood pressure, and rash, and the procedure was terminated without sequelae. Follow up IA infusion of temozolomide diluent in normal rats showed damaged cerebrovasculature as determined by dye leakage. These results demonstrate that IA infusion of temozolomide was toxic, with or without BBBD. We conclude that under the current formulation temozolomide is not safe for IA infusion in patients.

KW - Animal model

KW - Case study

KW - Chemotherapy

KW - Intra-arterial infusion

UR - http://www.scopus.com/inward/record.url?scp=84956597734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956597734&partnerID=8YFLogxK

U2 - 10.1007/s11060-015-2000-1

DO - 10.1007/s11060-015-2000-1

M3 - Article

C2 - 26694547

AN - SCOPUS:84956597734

VL - 126

SP - 447

EP - 454

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -